HIF1A and neoplasm: Finally and more interestingly, the rebound neoangiogenesis that occurs in case of sorafenib definitive withdrawal allows a quite complete tumor perfusion (as demonstrated also by the arterial enhancement quantification) leaving only minimal hypoxic areas and thus leading to a lower expression of HIF-1α (as demonstrated in our study).